|
Nov 28
|
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
|
|
Nov 27
|
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
|
|
Sep 26
|
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
|
|
Sep 19
|
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
|
|
Aug 10
|
New Strong Sell Stocks for August 10th
|
|
Aug 8
|
Why Shares of Arcturus Therapeutics Dropped on Tuesday
|
|
Aug 8
|
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2023 Earnings Call Transcript
|
|
Aug 8
|
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Cut Their EPS Forecasts Substantially
|
|
Aug 8
|
Q2 2023 Arcturus Therapeutics Holdings Inc Earnings Call
|
|
Aug 7
|
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 7
|
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
|